The Phase III trial will enroll over 300 people with Parkinson's disease, some of whom will receive the cough drug ambroxol. Reading time 3 minutes An important clinical trial for Parkinson’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback